Truist Financial Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Biogen (NASDAQ:BIIB) had its target price raised by stock analysts at Truist Financial from $190.00 to $193.00 in a research note issued to investors on Monday, MarketBeat.com reports. The firm presently has a “hold” rating on the biotechnology company’s stock. Truist Financial’s price objective would indicate a potential upside of 2.12% from the company’s previous close.

Several other equities analysts also recently weighed in on the stock. Oppenheimer lifted their target price on shares of Biogen from $205.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, January 30th. TD Cowen lifted their price objective on shares of Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday. UBS Group initiated coverage on Biogen in a research report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 target price on the stock. Morgan Stanley set a $190.00 price target on Biogen in a research report on Sunday. Finally, Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. Thirteen analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $207.81.

Biogen Stock Performance

NASDAQ:BIIB opened at $188.99 on Monday. The company has a market capitalization of $27.74 billion, a P/E ratio of 21.45, a P/E/G ratio of 1.55 and a beta of 0.16. The business has a fifty day simple moving average of $177.44 and a two-hundred day simple moving average of $157.89. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. Biogen has a 1 year low of $110.04 and a 1 year high of $202.41.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the prior year, the company earned $3.44 EPS. The firm’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, analysts expect that Biogen will post 15.83 earnings per share for the current year.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.18% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BIIB. Privium Fund Management B.V. bought a new position in shares of Biogen in the second quarter worth approximately $2,666,000. Nordea Investment Management AB raised its holdings in Biogen by 5.7% during the 2nd quarter. Nordea Investment Management AB now owns 125,935 shares of the biotechnology company’s stock valued at $15,810,000 after buying an additional 6,811 shares during the last quarter. Convergence Investment Partners LLC purchased a new stake in Biogen during the 3rd quarter valued at $1,342,000. Pitcairn Co. bought a new stake in Biogen in the 2nd quarter worth $936,000. Finally, Fluent Financial LLC bought a new stake in Biogen in the 3rd quarter worth $3,578,000. 87.93% of the stock is currently owned by institutional investors.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and updated guidance — Biogen reported Q4 results and FY guidance that topped expectations (EPS and revenue beats; FY2026 EPS range of 15.25–16.25), a key driver for recent analyst upgrades and higher targets. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The biologics license application for a subcutaneous formulation of Leqembi (lecanemab) was designated for priority review, which could materially expand the Alzheimer’s franchise if approved. Article Title
• Positive Sentiment: Multiple bullish analyst moves lift upside — Several firms raised price targets and/or maintained Buy ratings after the results and pipeline updates (Goldman Sachs PT raised to $231; RBC to $233; HC Wainwright to $228; Canaccord and others also raised targets), supporting multi-quarter upside expectations. Article Title
• Neutral Sentiment: Pipeline diversification headlines (lupus, SMA) — Management and coverage note advancing programs beyond Alzheimer’s, which improves long-term growth optionality but will take time to materialize. Article Title
• Neutral Sentiment: Mixed analyst stances — Several shops raised price targets but kept neutral/hold ratings (Citigroup, Piper Sandler, Wedbush, Truist), indicating disagreement on valuation even after beats. Article Title
• Neutral Sentiment: Short-interest report appears unreliable — A reported “significant increase” shows zero shares in the feed (data inconsistent); no clear short-covering pressure signaled. (internal short-interest entry)
• Negative Sentiment: Ongoing franchise pressure and execution risk — Coverage notes that legacy multiple sclerosis (MS) franchise pressures and execution on expanding Leqembi access/commercial scale remain risks that could cap near-term upside. Article Title

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.